© 2021 MJH Life Sciences and Opthalmology Times Europe. All rights reserved.
© 2021 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
December 10, 2020
John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.
December 09, 2020
Good early adherence to label regimens can make a difference, yielding vision outcomes approaching those in clinical trials, emerging real-world studies of anti-VEGF for DMO suggest.
December 07, 2020
Poorly focused YAG shots lead irrevocably to a permanent defect in the IOL material and thus to possible effects on the quality of vision with straylight or glare. In a recent study, the differing amounts of damage that Nd:YAG causes in a range of hydrophilic and hydrophobic acrylic lens materials was assessed.
December 03, 2020
As OCT-A devices become faster, the algorithms advance and the instrument costs decrease, more widespread utilisation in retina practices is likely.
December 01, 2020
The Malyugin ring 2.0 expands the small pupil safely and effectively to enable excellent intraoperative visualisation. It has a good safety record and is easier to use than alternative methods.
A panel of experts in ophthalmology and optometry review the diagnosis and treatment of diabetic eye disease including emerging agents in the field.
November 25, 2020
In this roundtable, members of the Ophthalmology Times Europe® Editorial Advisory Board consider the top challenges and opportunities that they anticipate will affect ophthalmology in Europe in 2021.
November 16, 2020
Robert Weinstock, MD, presents data from a retrospective multicenter study focusing on the efficacy of dexamethasone intraocular suspension 9% delivered at the time of cataract surgery.
November 15, 2020
During AAO 2020, Neal H. Shorstein, MD, explains how physicians at Kaiser Permanente have a streamlined regimen using a prophylactic drop-free drug before cataract surgery for more than a decade.
Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.